Similarly, in real-world data reported by Dourthe et al. (37), higher tumour burden, regardless of the cut-off used (>50 or ≥1%), was associated with longer CAR T-cell persistence but an increased risk of CD19− relapse, whereas a low tumour burden correlated with decreased persistence and increased risk of CD19+ relapse. Here, CD19 is linked to neoplasm.